Skip to main content
Premium Trial:

Request an Annual Quote

PamGene Raises 10M in Second Financing Round

NEW YORK, July 7 - Dutch microarray maker PamGene said today that it has raised 10 million ($11.4 million) in a second financing round led by LCF Rothschild Venture Partners.


Additional investors included Alta Partners, GIMV Venture Capital, and Life Sciences Partners. The new financing adds to a first-round investment of €6.7 million ($7.6 million) from these three firms in December 2000.


PamGene said the new funds would go toward development and marketing of its PamStation 96 microarray platform, which is scheduled to launch in the first quarter of 2004.


Raphael Wisniewski, investment manager at LCF Rothschild, will join PamGene's supervisory board, which is chaired by Jean Deleage of Alta Partners, and also includes Mark Wegter of LSP, Patrick van Beneden of GIMV, Ralph Martinke of Olympus, and Ton Stap of BioMerieux.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.